Abstract
IntroductionCell stimulation leads to the shedding of phosphatidylserine (PS)-rich microparticles (MPs). Because autoimmune diseases (AIDs) are characterized by cell activation, we investigated level of circulating MPs as a possible biomarker in primary Sjögren's syndrome (pSS), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).MethodsWe measured plasma levels of total, platelet and leukocyte MPs by prothrombinase capture assay and flow cytometry in 43 patients with pSS, 20 with SLE and 24 with RA and in 44 healthy controls (HCs). Secretory phospholipase A2 (sPLA2) activity was assessed by fluorometry. Soluble CD40 ligand (sCD40L) and soluble P-selectin (sCD62P), reflecting platelet activation, were measured by ELISA.ResultsPatients with pSS showed increased plasma level of total MPs (mean ± SEM 8.49 ± 1.14 nM PS equivalent (Eq), P < 0.0001), as did patients with RA (7.23 ± 1.05 n PS Eq, P = 0.004) and SLE (7.3 ± 1.25 nM PS Eq, P = 0.0004), as compared with HCs (4.13 ± 0.2 nM PS Eq). Patients with AIDs all showed increased level of platelet MPs (P < 0.0001), but only those with pSS showed increased level of leukocyte MPs (P < 0.0001). Results by capture assay and flow cytometry were correlated. In patients with high disease activity according to extra-glandular complications (pSS), DAS28 (RA) or SLEDAI (SLE) compared with low-activity patients, the MP level was only slightly increased in comparison with those having a low disease activity. Platelet MP level was inversely correlated with anti-DNA antibody level in SLE (r = -0.65; P = 0.003) and serum β2 microglobulin level in pSS (r = -0.37; P < 0.03). The levels of total and platelet MPs were inversely correlated with sPLA2 activity (r = -0.37, P = 0.0007; r = -0.36, P = 0.002, respectively). sCD40L and sCD62P concentrations were significantly higher in pSS than in HC (P ≤ 0.006).ConclusionsPlasma MP level is elevated in pSS, as well as in SLE and RA, and could be used as a biomarker reflecting systemic cell activation. Level of leukocyte-derived MPs is increased in pSS only. The MP level is low in case of more severe AID, probably because of high secretory phospholipase A2 (sPLA2) activity, which leads to consumption of MPs. Increase of platelet-derived MPs, sCD40L and sCD62P, highlights platelet activation in pSS.
Highlights
Cell stimulation leads to the shedding of phosphatidylserine (PS)-rich microparticles (MPs)
In patients with high disease activity according to extra-glandular complications, Disease Activity Score for 28 joints (DAS28) (RA) or SLE Disease Activity Index (SLEDAI) (SLE) compared with low-activity patients, the MP level was only slightly increased in comparison with those having a low disease activity
The levels of total and platelet MPs were inversely correlated with secretory phospholipase A2 (sPLA2) activity (r = -0.37, P = 0.0007; r = -0.36, P = 0.002, respectively). Soluble CD40 ligand (sCD40L) and sCD62P concentrations were significantly higher in primary Sjögren's syndrome (pSS) than in healthy controls (HCs) (P ≤ 0.006)
Summary
Cell stimulation leads to the shedding of phosphatidylserine (PS)-rich microparticles (MPs). A general feature of activated cells is their ability to shed fragments from their plasma membrane These fragments represent a heterogeneous population of small membrane-coated vesicles with diameter of 0.1 to 1 μm, termed microparticles (MPs) [1]. Exosomes are smaller than MPs and not generated from the plasma membrane but arise from the inside of cells in multivesicular bodies, and are mostly devoid of phosphatidylserine. MPs contain protein markers specific to the parental cell types, which allows for the detection of the cellular origin of MPs [2] These subcellular structures can transfer bioactive molecules from parental to target cells, allowing for regulation and amplification of several biological mechanisms such as apoptosis or cell activation (inflammatory or autoimmune responses, cell proliferation or coagulation). MPs could reflect parental cell stimulation and be involved in target cell stimulation [2]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
